🇺🇸 Fluticasone/Salmeterol Diskus in United States
12 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 12
Most-reported reactions
- Pancreatitis — 2 reports (16.67%)
- Respiratory Failure — 2 reports (16.67%)
- Alopecia — 1 report (8.33%)
- Ascites — 1 report (8.33%)
- Asthma — 1 report (8.33%)
- Bacteria Stool Identified — 1 report (8.33%)
- Cardiac Failure Congestive — 1 report (8.33%)
- Cholecystitis Acute — 1 report (8.33%)
- Cholelithiasis — 1 report (8.33%)
- Drug Hypersensitivity — 1 report (8.33%)
Fluticasone/Salmeterol Diskus in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Respiratory approved in United States
Frequently asked questions
Is Fluticasone/Salmeterol Diskus approved in United States?
Fluticasone/Salmeterol Diskus does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Fluticasone/Salmeterol Diskus in United States?
Johns Hopkins University is the originator. The local marketing authorisation holder may differ — check the official source linked above.